TIRZ (Tirzepatide) is a dual GIP/GLP‑1 receptor agonist used for improving blood sugar control and supporting significant weight loss. It is approved for type 2 diabetes and chronic weight management.

Key information and effects:

Tirzepatide activates both GIP and GLP‑1 receptors, enhancing insulin secretion, reducing glucagon, and slowing gastric emptying.

It can produce substantial weight loss by reducing appetite, increasing satiety, and improving metabolic efficiency.

Clinical trials show greater weight reduction than most GLP‑1–only medications.

It improves blood sugar control, often leading to lower A1C levels and reduced reliance on other diabetes medications.

Tirzepatide may improve cardiovascular markers, including blood pressure, cholesterol, and inflammation.

Some studies suggest potential benefits for fatty liver disease (NAFLD) by reducing liver fat.